Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.48 |
| ▸ | CTSS | P25774 | 5/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL617476 | 1.00 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL2564729 | 1.00 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL29454915 | 0.94 | CTSK (0.50) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL384624 | 0.92 | PPARA (0.47) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL2323692 | 0.92 | PPARA (0.47) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL6337223 | 0.92 | PPARA (0.47) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL3880876 | 0.92 | FOLH1 (0.42) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL17600320 | 0.90 | CTSK (0.52) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL17600321 | 0.90 | CTSK (0.52) | PPARAPPARGCTSKCTSSACE | |
| Benzene SCHEMBL28847299 | 0.89 | PPARA (0.51) | PPARAPPARGCTSKCTSSACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989091-B | Preparation method of glutaminyl ethyl imidazole | 水羊化妆品制造有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-115260160-B | Compound of targeted fibroblast activation protein FAP, preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-115260160-A | Compound of targeted fibroblast activation protein FAP and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115260278-A | Preparation method and application of cryptotanshinone self-assembled prodrug micelle nanoparticles | 南方医科大学 | 2022-11-01 | — | — | CN | claimed |
| CN-114989091-A | Preparation method of glutamyl ethyl imidazole | 水羊化妆品制造有限公司 | 2022-09-02 | — | — | CN | claimed |
| EP-0549727-A1 | CARBOXYLIC ACID ESTERS OF RAPAMYCIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-07-07 | — | — | EP | claimed |
| US-5130307-A | Antibody inhibitors; treating organ graft rejection, fungal infections; antiinflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-14 | — | — | US | claimed |
| WO-1992005179-A1 | CARBOXYLIC ACID ESTERS OF RAPAMYCIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-04-02 | — | — | WO | claimed |
| US-20260008750-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING PRODUCTION OF TRIMETHYLAMINE | CLEVELAND CLINIC FOUND (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-3778597-B1 | TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USES THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025049064-A9 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-0655065-B1 | 27-HYDROXYRAPAMYCIN AND DERIVATIVES THEREOF | AMERICAN HOME PROD (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0655065-A1 | 27-HYDROXYRAPAMYCIN AND DERIVATIVES THEREOF. | AMERICAN HOME PROD (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5302600-A | Inducing immunosuppression; antiinflammatory agents, antifungal, antitumor and antiproliferative agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-12 | — | — | US | disclosed |
| WO-1994004540-A1 | 27-HYDROXYRAPAMYCIN AND DERIVATIVES THEREOF | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5256790-A | Antibiotic | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| US-5130307-A | Antibody inhibitors; treating organ graft rejection, fungal infections; antiinflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | PPARA 2646/4885PPARG 2722/4885CTSK 301/4885 |
| US-20260008750-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING PRODUCTION OF TRIMETHYLAMINE | SLC6A6, BHMT2, BHMT | PPARA 2593/4885PPARG 3234/4885CTSK 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.